Navigation Links
Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
Date:1/9/2008

JUNCTION CITY, Kan., Jan. 9 /PRNewswire/ -- Ventria Bioscience announced today that Angus Connell would be joining the company as Director of Bioprocessing Operations for the company's Junction City facility.

Connell, a Kansas native, has extensive experience in operations, engineering design and process development leadership with Koch Industries and Coffeyville Resources. At Koch Industries, he held positions including Manager of Process Engineering and Director of Engineering and Research. He was most recently the Operations Manager for Coffeyville Resources. Angus received his Bachelor of Science degree in Chemical Engineering from the University of Tulsa.

"Angus brings a wealth of process engineering, operations management, and plant expansion capabilities to our team in Junction City," said Greg Unruh, Vice President and General Manager, Ventria Bioscience. "His experience is vital as we continue with the expansion of our facility. We are continually searching for talented employees with engineering, biology and agronomy experience to fill open positions in our Kansas operations. Many of the candidates we have hired in the last year have been trained by Kansas State University, University of Kansas, McPherson College and other Kansas-based educational institutions. Many are Kansas natives, like Angus, who are looking for the opportunity to become part of the bioscience industry in their home state of Kansas," he said.

"I am quite happy for the opportunity to remain in Kansas, at the same time I get to work in a cutting edge industry where I can continue to learn. My other opportunities would have required me to leave Kansas in order to advance my career," said Connell.

About Ventria

A recent child health study showed that Ventria's Lactiva and Lysomin helped reduce the duration of diarrhea in children by 30 percent when added to rehydration solutions. Childhood diarrhea is the second leading killer of children, claiming 2 million lives annually according to the World Health Organization.

For more information, see our website: http://www.ventria.com

Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.


'/>"/>
SOURCE Ventria Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Science Teachers Tour Ventrias Bioprocessing Facility
2. Symmetry Medical Expands Board of Directors
3. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
4. Observant LLC Expands Senior Management Team
5. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
6. HealthTrust Expands Contract With Instrumentation Laboratory for Critical Care Portfolio to Include Consorta
7. CSL Behring Expands Into Middle East Market with Haemate(R) P
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
10. Siemens Expands the SOMATOM Definition(TM) Line With Worlds First Adaptive CT Scanner
11. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... and sale of advanced technology solutions and products to ... announced the addition of new cohorts of PDX models ... models will expand Champions, product line in hepatocellular cancer, ... cancer, AML, and non-small cell lung cancer (including EGFR ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):